Orbis Biosciences is dedicated to building long-term strategic relationships with its partners. Our goal is to enable our partners with differentiated products that drive incremental value within their existing product portfolios while creating new intellectual property to extend the life of our partner’s assets. Orbis’ technology is compatible with small molecule, proteins, and peptides.


In addition to partnering with pharmaceutical companies, Orbis also opportunistically develops its own products as technology proof points to demonstrate the capabilities of our three proprietary technology platforms; Optimµm® platform for oral drug delivery, Stratµm™ platform for injectable drug delivery, and Unisun® platform for localized drug delivery to the inner ear. These products are available for out-licensing to companies that are positioned to realize the value potential of these assets.